Wall Street expects a year-over-year increase in earnings on higher revenues when BioCryst Pharmaceuticals (BCRX) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on A ...